While NewAmsterdam Pharma Company NV has overperformed by 0.39%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NAMS rose by 130.08%, with highs and lows ranging from $27.29 to $11.18, whereas the simple moving average jumped by 30.69% in the last 200 days.
On December 30, 2024, H.C. Wainwright started tracking NewAmsterdam Pharma Company NV (NASDAQ: NAMS) recommending Buy. A report published by TD Cowen on May 15, 2024, Initiated its previous ‘Buy’ rating for NAMS. Scotiabank also rated NAMS shares as ‘Sector Outperform’, setting a target price of $35 on the company’s shares in an initiating report dated March 14, 2024. Guggenheim Initiated an Buy rating on January 18, 2024, and assigned a price target of $30. Piper Sandler initiated its ‘Overweight’ rating for NAMS, as published in its report on January 16, 2024. RBC Capital Mkts’s report from October 30, 2023 suggests a price prediction of $25 for NAMS shares, giving the stock a ‘Outperform’ rating.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analysis of NewAmsterdam Pharma Company NV (NAMS)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of NewAmsterdam Pharma Company NV’s future performance, with equity being one of the most critical indicators. Taking into account the quick ratio of the company, currently set at 10.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and NAMS is recording an average volume of 737.85K. On a monthly basis, the volatility of the stock is set at 6.06%, whereas on a weekly basis, it is put at 2.75%, with a gain of 0.27% over the past seven days. Furthermore, long-term investors anticipate a median target price of $43.44, showing growth from the present price of $25.70, which can serve as yet another indication of whether NAMS is worth investing in or should be passed over.
How Do You Analyze NewAmsterdam Pharma Company NV Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 52.78%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 35.74% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
NAMS shares are owned by institutional investors to the tune of 35.74% at present.
